Dichloroacetate causes toxic neuropathy in MELAS

  title={Dichloroacetate causes toxic neuropathy in MELAS},
  author={Petra Kaufmann and Kristin M Engelstad and Y. H. Wei and Sarah Jhung and Mary Sano and Dikoma C. Shungu and W. S. Millar and Xu Hong and Clifton L. Gooch and Xiangling Mao and Juan M. Pascual and Michio Hirano and Peter W. Stacpoole and Salvatore Dimauro and Darryl C De Vivo},
  pages={324 - 330}
Objective: To evaluate the efficacy of dichloroacetate (DCA) in the treatment of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Background: High levels of ventricular lactate, the brain spectroscopic signature of MELAS, correlate with more severe neurologic impairment. The authors hypothesized that chronic cerebral lactic acidosis exacerbates neuronal injury in MELAS and therefore, investigated DCA, a potent lactate-lowering agent, as potential… 

Figures and Tables from this paper

Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS)
The pathophysiology of stroke-like episodes suggests a role of nitric oxide deficiency and endothelial dysfunction resulting in segmental vasoconstriction resulting in significant neurological disability.
Controlled Clinical Trial of Dichloroacetate for Treatment of Congenital Lactic Acidosis in Children
In this highly heterogeneous population of children with congenital lactic acidosis, oral DCA for 6 months was well tolerated and blunted the postprandial increase in circulating lactate, but it did not improve neurologic or other measures of clinical outcome.
MELAS masquerading as a systemic vasculitis.
  • M. Carroll
  • Medicine, Psychology
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • 2007
The case of a 26-year-old white man suspected with primary central nervous system vasculitis admitted to the authors' facility with profound constipation from severe intestinal dysmotility illustrates the importance of considering a mitochondrial genetic disorder in the differential diagnosis of patients who present to Rheumatologists with suspected unusual or atypical vasculitic symptoms.
Dichloroacetate-induced peripheral neuropathy.
Treatment is multifactorial and supportive, including optimization of nutrition and deficiency, gastrostomy tube if necessary, treatment of secondary neurologic issues, vitamin and cofactor therapy (creatine monohydrate, coenzyme Q10, α-lipoic acid, etc), and exercise.
Severe encephalopathy and polyneuropathy induced by dichloroacetate
For the first time, a patient with melanoma is presented who developed encephalopathy and grade III sen-sorimotor polyneuropathy after 4 weeks of DCA treatment, and DCA washailed as a ‘miracle drug’ on internet-based patient forums.
Stroke-Like Episodes in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS)
The mechanisms of mitochondrial inheritance, including concepts such as heteroplasmy and mitotic segregation that underlay the complex genetics of this disease, are discussed.
Anesthetic considerations in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome: a case series
The MELAS patients developed episodes of hyponatremia and hyperkalemia of variable severity unrelated to the timing of surgery, suggesting these patients are prone to major electrolyte disturbances.
Review of Clinical Trials for Mitochondrial Disorders: 1997–2012
  • D. Kerr
  • Medicine
  • 2013
Despite the paucity of benefits found so far, well-controlled clinical trials are essential building blocks in the continuing search for more effective treatment of mitochondrial disease, and current trials based on information gained from these prior experiences are in progress.
The Mitochondrial Myopathy Encephalopathy, Lactic Acidosis with Stroke-Like Episodes (MELAS) Syndrome
Current approaches to the treatment of the MELAS syndrome are based on the use of antioxidants, respiratory chain substrates and cofactors in the form of vitamins; however, no consistent benefits have been observed with these treatments.


Therapeutic effect and [123I]IMP SPECT findings of sodium dichloroacetate in a patient with MELAS
A 16-year-old girl with MELAS, who had progressive anorexia and speech deterioration and responded to DCA treatment clinically and on neuroimaging, is examined, finding an A-to-G transition at nucleotide 3,243 in the mitochondrial DNA in her and her mother’s leukocytes.
Cerebral lactic acidosis correlates with neurological impairment in MELAS
High levels of ventricular lactate, the brain spectroscopic signature of MELAS, are associated with more severe neurologic impairment, and the role of chronic cerebral lactic acidosis in the pathogenesis of M ELAS is evaluated.
Short‐term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders
It is indicated that short-term DCA treatment not only lowers blood lactate but also improves indices of both brain oxidative metabolism and neuronal and glial density or function.
Effects of dichloroaeetate in three patients with MELAS
DCA ameliorated abdominal pain, headache, and strokelike episodes, and improved cognitive function and fatigability in the three patients during the study period.
Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate
Serial measurements of nerve conduction velocities and amplitudes were performed in 27 patients with congenital lactic acidemia over 1 year of sodium dichloroacetate (DCA) administration, and peripheral neuropathy appears to be a common side effect during chronic DCA treatment, even with coadministration of oral thiamine.
Chronic treatment of mitochondrial disease patients with dichloroacetate.
Defective activation of the pyruvate dehydrogenase complex in subacute necrotizing encephalomyelopathy (leigh disease)
Enzymological observations point to an in vivo defect in the activation mechanism of the pyruvate dehydrogenase complex as the biochemical disturbance in SNE, and suggest that dichloroacetate may be beneficial in treating SNE.
A Controlled Clinical Trial of Dichloroacetate for Treatment of Lactic Acidosis in Adults
A placebo-controlled, randomized trial of intravenous sodium dichloroacetate therapy in 252 patients with lactic acidosis, finding that it might reduce morbidity and improve survival among patients with this condition.